Andy Birchfield in the News

Photo of Andy Birchfield Andy D. Birchfield , Jr.
Lead Attorney in $4.85 Billion Vioxx Settlement
 

Articles 91 to 100 of 100 for attorney Andy Birchfield .

Senate investigators interview lawyer who has sued Merck

The New York Times | November 2, 2004

Senate investigators examining Merck's recall of its Vioxx painkiller have interviewed an Alabama lawyer whose firm has filed 58 lawsuits against the company on

Lawyers look to Vioxx recall to Boost Plaintiffs Cases

| October 25, 2004
Plaintiffs' attorneys are predicting that Merck & Co.'s recall of Vioxx will significantly enhance their odds of convincing jurors that the popular arthritis medication caused their clients' heart attacks and strokes.

Response to Merck's Press Conference regarding Vioxx

| October 13, 2004
Merck's press conference was very disappointing, according to Andy Birchfield, "Instead of accepting responsibility for putting a dangerous drug on the market and keeping it there for so long, Merck spent an hour defending itself."

Merck's Pain Sharpens

| October 11, 2004
The final bill for Merck's Vioxx is just beginning to be toted up before it pulled Vioxx off the market because of the cardiac risks the painkiller could pose to long-term users.

Vioxx Lawsuits may be difficult to Prove

| October 10, 2004
Evelyn Irvin Plunkett said she remembers the day her husband starting taking Vioxx for back pain. It was April 15, 2001.

Merck braces for another Deluge of Lawsuits by Vioxx Users

| October 3, 2004
Following Merck & Co.'s withdrawal of the blockbuster painkiller Vioxx, patients, shareholders and even the company began scrambling to figure out their next moves.

Merck braces for wave of Vioxx Lawsuits

| October 3, 2004
The flood of phone calls to plaintiffs' lawyers began soon after pharmaceutical giant Merck & Co. announced that it would withdraw its painkiller Vioxx from the market because of safety concerns.

A Blow to Efforts to Close in on Rivals

| October 1, 2004
Merck & Company's decision to stop selling the painkiller Vioxx, one of its most profitable drugs, could hardly have come at a worse time for the company.

Merck recalls Vioxx

| September 30, 2004
A new FDA study found patients taking a high dose of Vioxx were three times more likely to have a heart attack. As a result, Merck & Co. is pulling the arthritis drug from the market.

Teen Death Stirs Fresh Debate About Depression Medication

The Wall Street Journal | April 20, 2004
The death of a teenager last week from liver failure is raising questions anew about an antidepressant that continues to be available in the U.S. despite having been removed from the market in other countries.